Neutrophil-to-lymphocyte ratio in malignant pleural fluid: Prognostic significance.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
24
11
2020
accepted:
10
04
2021
entrez:
26
4
2021
pubmed:
27
4
2021
medline:
5
10
2021
Statut:
epublish
Résumé
Predicting survival of patients with malignant pleural effusions (MPEs) is notoriously difficult. A robust prognostic marker can guide clinical decision making. The neutrophil-to-lymphocyte ratio (NLR) in blood has been shown to predict survival in many cancers. Pleural fluid bathes the malignant pleural tissues, thus the NLR of the pleural fluid may reflect more closely the local tumour environment. The objective of this study was to explore the prognostic significance of pleural effusion NLR for MPE. We analysed matched effusion and blood from 117 patients with malignant and 24 with benign pleural effusions. Those who had received recent chemotherapy or had a pleurodesis were excluded. Neutrophil and lymphocyte counts in effusions were performed by manual review of cytospin cell preparations by trained observers. Clinical data were extracted from a state-wide hospital database. We found significantly fewer neutrophils (expressed as percentage of total leukocyte count) in pleural fluid than in corresponding blood (9% vs 73%; p<0.001). The NLR was an order of magnitude lower in pleural fluid than in corresponding blood: median [IQR] = 0.20 [0.04-1.18] vs 4.9 [3.0-8.3], p<0.001. Correlation between blood and pleural fluid NLR in MPE patients was moderate (rs = 0.321, p<0.001). In univariate analysis, NLR (>0.745)) in malignant pleural fluid was predictive of poorer survival (HR = 1.698 [1.0054-2.736]; p = 0.030), and remained significant after adjustment for age, sex, presence of a chest drain, cancer type, concurrent infection and subsequent treatment with chemotherapy (HR = 1.786 [1.089-2.928]; p = 0.022). Patients with pleural fluid NLR > 0.745 had a significantly shorter median survival of 130 (95% CI 0-282) days compared to 312 (95% CI 195-428) days for pleural NLR < 0.745, p = 0.026. The NLR in blood was also predictive of poorer survival in MPE patients (HR = 1.959 [1.019-3.096]; p<0.001). The proportion of neutrophils in pleural fluid was predictive of prognosis more strongly than lymphocytes. This study provides evidence that NLR in malignant effusions can predict survival, and therefore may provide prognostic information for this cohort. This prognostic association in the fluid is driven by the presence of neutrophils.
Identifiants
pubmed: 33901252
doi: 10.1371/journal.pone.0250628
pii: PONE-D-20-36963
pmc: PMC8075197
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0250628Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Natl Cancer Inst. 2014 May 29;106(6):dju124
pubmed: 24875653
In Vivo. 2020 Jul-Aug;34(4):2179-2185
pubmed: 32606202
Head Neck. 2012 Dec;34(12):1769-76
pubmed: 22318781
J Thorac Cardiovasc Surg. 2009 Feb;137(2):425-8
pubmed: 19185164
J Breast Cancer. 2013 Mar;16(1):55-9
pubmed: 23593082
Respir Med. 2011 Jan;105(1):137-42
pubmed: 21041073
J Thorac Oncol. 2012 Mar;7(3):587-94
pubmed: 22307011
Chest. 1992 Oct;102(4):1055-9
pubmed: 1395742
Crit Rev Oncol Hematol. 2013 Oct;88(1):218-30
pubmed: 23602134
Gastric Cancer. 2010 Aug;13(3):170-6
pubmed: 20820986
BMC Cancer. 2013 Mar 27;13:158
pubmed: 23530866
Thorax. 2010 Aug;65 Suppl 2:ii32-40
pubmed: 20696691
Clin Cancer Res. 2010 Dec 1;16(23):5805-13
pubmed: 20956618
Eur J Cancer. 2009 Jul;45(11):1950-8
pubmed: 19231158
Curr Opin Pulm Med. 2002 Jul;8(4):294-301
pubmed: 12055392
Thorax. 2014 Dec;69(12):1098-104
pubmed: 25100651
BMC Pulm Med. 2015 Mar 28;15:29
pubmed: 25887349
BMC Cancer. 2015 Aug 21;15:594
pubmed: 26292807
Cancer Res. 1999 Jan 15;59(2):367-71
pubmed: 9927048
Chest. 2000 Jan;117(1):79-86
pubmed: 10631203
Front Immunol. 2015 Sep 14;6:471
pubmed: 26441976
Respiration. 2014;87(4):311-6
pubmed: 24457947
N Engl J Med. 1991 Jul 18;325(3):164-70
pubmed: 1711156
Ann Intern Med. 1972 Oct;77(4):507-13
pubmed: 4642731
Clin Transl Oncol. 2012 Nov;14(11):864-9
pubmed: 22855161
Biomarkers. 2010 Sep;15(6):516-22
pubmed: 20602543
Cancer Microenviron. 2015 Dec;8(3):125-58
pubmed: 24895166
Exp Eye Res. 2012 Feb;95(1):35-9
pubmed: 21855543
Br J Cancer. 2003 Feb 10;88(3):348-53
pubmed: 12569375
Br J Cancer. 2005 Aug 8;93(3):273-8
pubmed: 16052222